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http://dx.doi.org/10.1016/j.ccr.2012.11.017SUMMARYRecognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive efforts to develop
targeted pathway inhibitors. Leading inhibitors in clinical development act by binding to a common site within
Smoothened, a critical pathway component. Acquired Smoothened mutations, including SMOD477G, confer
resistance to these inhibitors. Here, we report that itraconazole and arsenic trioxide, two agents in clinical
use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists,
retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants
and GLI2 overexpression. Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth
of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-
resistant SMOD477G medulloblastoma.INTRODUCTION
The Hedgehog (Hh) signaling pathway is critical for embryonic
patterning (Varjosalo and Taipale, 2008) and functions postna-
tally in tissue homeostasis through its action on stem or progen-Significance
Small molecule Hedgehog pathway antagonists currently bein
ened in a manner competitive with cyclopamine. Resistance t
in Smoothened has been described in relevant animal models a
available FDA-approved drugs with well-defined pharmacokin
context of wild-type or resistant Smoothened mutants, in vit
Hedgehog pathway inhibitors that could be introduced rapidl
dependent tumors and those with acquired resistance to Smoitor cells (Beachy et al., 2004; Shin et al., 2011). Aberrant Hh
signaling has been implicated in oncogenesis, maintenance of
tumor progenitor cells, and tumor-stromal interaction in a diverse
array of cancers, including tumors that arise sporadically or from
individuals with heritable pathway mutations (Teglund andg evaluated in cancer clinical trials act by binding Smooth-
o these cyclopamine mimics caused by acquired mutations
nd in patients. Itraconazole and arsenic trioxide, two readily
etics and relatively mild toxicity profiles, have activity in the
ro and in vivo. Itraconazole and arsenic trioxide are active
y into clinical trials for the treatment of de novo Hedgehog-
othened inhibitors.
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Figure 1. A Simplified View of Hh Signaling
Binding of a Hh ligand to Patched (PTCH) derepresses SMO, causing acti-
vation and translocation to the nucleus of GLI2, which initiates the transcription
of target genes, including PTCH and GLI1. Cyclopamine, its derivative, IPI-
926, and its mimics, GDC-0449 and NVP-LDE225, all bind competitively to
a site within the transmembrane portion of SMO; the SMOmissensemutations
indicated by yellow asterisks decrease binding and confer resistance to these
drugs. Itraconazole inhibits SMO by a distinct mechanism, and ATO inhibits
the pathway at the level of GLI.
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Targeting GDC-0449-Resistant Hh SignalingToftga˚rd, 2010). This has led to large-scale efforts by multiple
pharmaceutical companies to develop Hh pathway antagonists
for therapeutic use.
Hh pathway activity is regulated by Patched (PTCH), a 12-pass
transmembrane protein that suppresses the activity of Smooth-
ened (SMO), a 7-pass transmembrane protein that traffics
constitutively through the primary cilium (Kim et al., 2009; Ocbina
and Anderson, 2008). Upon binding of an Hh protein ligand to
PTCH, this suppression is relieved, leading to SMO activation
and accumulation in the primary cilium (Corbit et al., 2005; Kim
et al., 2009; Rohatgi et al., 2007). The GLI2 transcription factor,
which also traffics through the cilium, consequently is activated
and translocates to the nucleus (Kim et al., 2009), where it acti-
vates transcription of Hh-dependent target genes, including
PTCH1 and GLI1 (Figure 1).
The first Hh-dependent tumorswere described in patients with
Gorlin syndrome (Gorlin, 1987) (also called basal cell nevus24 Cancer Cell 23, 23–34, January 14, 2013 ª2013 Elsevier Inc.syndrome), an autosomal dominant condition associated with
germline loss of one copy of the PTCH1 gene (Gailani et al.,
1992; Hahn et al., 1996; Johnson et al., 1996). Themost common
tumors arising in these patients are basal cell carcinoma (BCC) of
the skin, medulloblastoma (MB), and, more rarely, rhabdomyo-
sarcoma (Gorlin, 1987). Hh pathway upregulation has been
found in essentially all cases of BCC (Epstein, 2008), including
sporadic BCC, with90% containing PTCH1mutations (Aszter-
baum et al., 1998; Gailani et al., 1996) and10%containing acti-
vating mutations in SMO (Reifenberger et al., 1998; Xie et al.,
1998). Hh-dependent MB (Goodrich et al., 1997; Mao et al.,
2006) accounts for approximately one-third of all MB (Monje
et al., 2011) and is associated with intermediate prognosis
(Cho et al., 2011; Ellison et al., 2011; Northcott et al., 2011).
SMO, as a central regulator of the pathway and an accessible
cell membrane component, has been the primary focus in
the development of small molecule Hh pathway inhibitors.
Cyclopamine, the archetypical SMO antagonist, was first
described as a steroidal alkaloid teratogen from the corn lily
associated with cyclopic lambs (Keeler and Binns, 1966; Keeler
and Binns, 1968), and was later determined to be a SMO antag-
onist (Chen et al., 2002; Cooper et al., 1998; Taipale et al., 2000).
Of the many SMO inhibitors in development, four have
progressed into phase II trials, including vismodegib (GDC-
0449; Genentech), NVP-LDE225 (Novartis), IPI-926 (Infinity),
and XL-139 (BMS/Exelixis); IPI-926 is derived from cyclopamine,
and all of these inhibitors compete with cyclopamine binding
to SMO (S.B. Gendreau and J. Fargnoli, 2009, Mol. Cancer
Ther., abstract; Pan et al., 2010; Robarge et al., 2009;
Tremblay et al., 2009). GDC-0449 was recently approved
for use as a first-line therapy in advanced unresectable BCC
(Jefferson, 2012).
The limited mechanistic diversity represented by clinically
developed Hh pathway inhibitors has become a focus of clinical
concern due the emergence of resistant SMO mutants. The first
case of SMOantagonist resistance was reported in a patient with
metastatic MB initially highly responsive to GDC-0449 (Rudin
et al., 2009). Gene sequencing of recurrent, drug-resistant
tumors from this patient identified a SMO missense mutation,
D473H, that decreased the binding affinity of GDC-0449 by
100-fold. A homologous mouse mutation, D477G, was found
in resistant murine Ptch+/;p53/ MB generated in vivo by
repetitive cycles of treatment with GDC-0449 (Yauch et al.,
2009). Another GDC-0449-resistant mutant, E518K, subse-
quently was identified in human SMO (Dijkgraaf et al., 2011).
Development of in vivo resistance to another SMO antagonist,
NVP-LDE225, was demonstrated in murine MB, with mutations
occurring at residues L225, N223, S391, D388, and G457
(Buonamici et al., 2010). The latter reports also identified other
putative mechanisms of resistance, including Gli2 and Ccnd1
amplification, and activation of the PI3K-AKT-mTOR signaling
pathway.
We have previously identified itraconazole, an FDA-approved
triazole antifungal agent, and arsenic trioxide (ATO), which is
FDA-approved for the treatment of acute promyelocytic
leukemia (APL), as potent inhibitors of the Hh pathway (Kim
et al., 2010a; Kim et al., 2010b). Itraconazole inhibits Hh
pathway activation at the level of SMO at a site distinct from
that of cyclopamine mimics currently in development, and by
Figure 2. Itraconazole Inhibits the Hh
Pathway in the Context of GDC-0449 Resis-
tant SMOD477G
(A and B) Relative Hh pathway activity as deter-
mined by expression of 83-GLI-luciferase reporter
in SHH-N stimulated Smo/ MEFs expressing
SMOWT (blue) or SMOD477G (red) treated with (A)
GDC-0449 or (B) itraconazole. Data represent
mean of triplicates ± SD.
(C and D) Proliferation of Ptch+/; p53/ MB tu-
morspheres expressing endogenous SMOWT
(blue) or SMOD477G (red) treated with increasing
doses of (C) GDC-0449 and (D) itraconazole. Data
represent mean of quadruplicates ± SEM.
(E and F) Relative Gli1 mRNA transcription in (C)
GDC-0449-treated and (D) itraconazole-treated
MB tumorspheres expressing endogenous
SMOWT (blue) or SMOD477G (red). Data represent
mean of quadruplicates ± SEM.
See also Figure S1.
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Targeting GDC-0449-Resistant Hh Signalinga mechanism distinct from its antifungal target of lanosterol-14a
demethylase (Kim et al., 2010b).
ATO directly binds to the zinc finger motif of the promyeloge-
nous leukemia-retinoic acid receptor fusion protein (PML-
RARa), the causative factor of APL (de The´ et al., 1990, 1991;
Rowley et al., 1977), and promotes its degradation (Lallemand-
Breitenbach et al., 2008; Zhang et al., 2010). Similarly, ATO
inhibits Hh signaling by inhibiting GLI2 ciliary accumulation and
promoting its degradation (Kim et al., 2010a). ATO also inhibited
the growth of Ewing Sarcoma tumors overexpressing GLI1 due
to direct transcriptional activation by the EWS-FLI1 fusion onco-
protein (Beauchamp et al., 2009, 2011; Joo et al., 2009; Zwerner
et al., 2008).
The occurrence of drug-resistant SMO mutations highlights
the therapeutic need for agents capable of maintaining robust
on-target clinical responses. Small molecule compounds that
overcome resistance to murine SMOD477G (Dijkgraaf et al.,
2011; Tao et al., 2011) or human SMOD473H (Dijkgraaf et al.,
2011) have been reported recently, but with no clear timeline
for clinical development. As FDA-approved drugs, itraconazole
and ATO represent readily available agents with distinct modes
of Hh pathway inhibitory activity. Therefore, we sought to test
the efficacy of itraconazole and ATO, as single agents and in
combination, to inhibit Hh pathway activity and growth of tumors
with drug-resistant SMO mutations.Cancer Cell 23, 23–3RESULTS
Itraconazole Inhibits GDC-0449-
Resistant Pathway Activity
Mediated by SMOD477G
Because itraconazole acts on SMO at
a site distinct from that of cyclopamine
and cyclopamine mimics (Kim et al.,
2010b), we hypothesized that itracona-
zole may have activity against the GDC-
0449 resistance mutant, SMOD477G
(Yauch et al., 2009). First, we evaluated
the ability of itraconazole to inhibit Hhpathway activity in the context of SMOWT or SMOD477G expres-
sion. SmoWT or SmoD477G were cotransfected with 8 3 -GLI
binding site firefly luciferase and SV40-Renilla reporters (Taipale
et al., 2000) into aSmo/mouse embryonic fibroblast (MEF) cell
line (Varjosalo et al., 2006) and treated with SHH-N conditioned
medium (CM) (Maity et al., 2005). As expected, GDC-0449
was active against SMOWT, but unable to inhibit SMOD477G
(Figure 2A). In contrast, itraconazole potently inhibited both
SMOWT and SMOD477G (Figure 2B), although the maximal inhibi-
tion of SMOD477G activity up to a concentration of 5 mM itracona-
zole left a residual 30% activity (Figure 2B). Itraconazole thus
acts as a full antagonist of SMOWT and as a partial antagonist
of SMOD477G. Similar to human SMOD473H (Yauch et al., 2009),
murine SMOD477G was less susceptible to inhibition by KAAD-
cyclopamine, as evidenced by the rightward shift of the mutant
dose-response curve (Figure S1A available online). However,
unlike GDC-0449, KAAD-cyclopamine was able to fully inhibit
SMOD477G activity at higher doses.
To evaluate itraconazole activity against Hh-dependent
tumors, we tested the ability of itraconazole to inhibit pathway
activity in tumorsphere cultures established using MB cells
with constitutive Hh pathway activity from Ptch+/;p53/ mice
(Berman et al., 2002; Goodrich et al., 1997; Romer et al.,
2004). When cultured in neural stem cell medium, these cells
grow in an Hh pathway-dependent manner and form4, January 14, 2013 ª2013 Elsevier Inc. 25
Figure 3. Itraconazole Combines with Cy-
clopamine to Inhibit GDC-0449-Resistant
SMO Function
(A) Relative 83-GLI-luciferase expression in
SHH-N-stimulated Smo/ MEFs expressing
SMOWT or SMOD477G, treated with GDC-0449,
itraconazole, or both.
(B) Effect of KAAD-cyclopamine 100 nM, itraco-
nazole 2 mM, or both on SHH-N-stimulated
83-GLI-luciferase expression in Smo/ MEFs
expressing SMOD477G.
(C) Dose-response curves of KAAD-cyclopamine
for SHH-N activated signaling in Smo/ MEFs
expressing SMOD477G, in the presence or absence
of itraconazole. All data represent mean of
triplicates ± SD.
See also Figure S2 and Table S1.
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CD-15+ cell population (Ward et al., 2009) (Read et al., 2009;
Shi et al., 2011). We utilized tumorsphere cultures derived from
allografts of parental SMOWT and derivative SG274 MB cells
that express spontaneously acquired SMOD477G (Dijkgraaf
et al., 2011; Yauch et al., 2009) to examine the differential
potency of itraconazole in an endogenous system of drug resis-
tance. The SMOD477G-expressing tumorspheres were100-fold
less sensitive than parental SMOWT tumorspheres to antiprolifer-
ative activity of GDC-0449 by MTS analysis (Figure 2C). In this
system, itraconazole displayed equivalent antiproliferative
activity in the parental (IC50 55 nM; 50–60 nM confidence interval
[CI]) and SMOD477G mutant MB cells (62 nM; 53–70 nM CI) (Fig-
ure 2D). Inhibition of Hh pathway activity, as monitored by Gli1
mRNA levels, correlated with the antiproliferative potencies of
GDC-0449 (Figure 2E) and itraconazole (Figure 2F). In contrast
to the Smo/MEF reporter-based signaling assay, itraconazole
fully inhibited proliferation and Hh pathway activity in the SMOWT
and GDC-0449-resistant MB cultures. MB spheres also were
more sensitive to itraconazole, with 100 nM IC50 for Gli1
mRNA transcription compared to600 nM IC50 for the luciferase
reporter assay in Smo/ MEFs. HhAntag (Gabay et al., 2003;
Romer et al., 2004), a SMO antagonist structurally distinct from
GDC-0449 and cyclopamine, has been reported to inhibit
SMOD473H at 1 mM (25 3 IC50 for SMOWT) (Dijkgraaf et al.,
2011). Pathway inhibition by HhAntag, as measured by Gli1
mRNA, showed a similar behavior to that of KAAD-cyclopamine
(Figure S1A), in that its inhibition curve shifts to the right (Fig-
ure S1B). The decrease in potency of HhAntag and KAAD-
cyclopamine in the context of SMOD477G is consistent with26 Cancer Cell 23, 23–34, January 14, 2013 ª2013 Elsevier Inc.previous reports for other inhibitors that
compete for cyclopamine binding to
SMO (Dijkgraaf et al., 2011; Lee et al.,
2012).
Combination of Itraconazole and
Cyclopamine Can Inhibit SMOD477G
Because we previously showed that itra-
conazole and KAAD-cyclopamine syner-
gize to inhibit SMOWT (Kim et al., 2010b)
and that these drugs act at distinct sites(Kim et al., 2010b), we hypothesized that itraconazole might
also act synergistically with cyclopamine mimics to inhibit the
activity of SMOD477G. We found, however, that addition of
GDC-0449 did not enhance itraconazole inhibitory potency
against SMOD477G, suggesting that GDC-0449 does not
contribute to pathway suppression in the combination (Fig-
ure 3A). Combination of itraconazole and KAAD-cyclopamine
completely inhibited SMOD477G activity at doses that are partially
inhibitory for the individual agents (Figure 3B). The addition of
itraconazole to KAAD-cyclopamine did not shift the IC50 of
KAAD-cyclopamine (Figure 3C; Figure S2; Table S1), suggesting
that the two drugs inhibit SMOD477G additively.
Itraconazole and Arsenic Trioxide Combine to Inhibit
Hh Pathway Activity and Tumor Growth
Because ATO inhibits the Hh pathway at the level of GLI proteins
(Kim et al., 2010a) and itraconazole acts on SMO, we hypothe-
sized that the two drugs might synergize in pathway inhibition.
We tested the drug combination against SMOWT in transiently
transfected NIH 3T3 cells using fixed doses of one drug while
titrating the other. The combination of itraconazole and ATO
improves Hh pathway inhibition (Figures 4A and 4B), but this
effect appears additive rather than synergistic, because there
is no leftward shift of IC50 for either drug (Figures 4A and 4B;
Figures S3A and S3B; Tables S2 and S3).
We next tested the itraconazole/ATO combination in tumor
growth inhibition in vivo using a subcutaneous allograft model
of Ptch+/;p53/ mouse MB. Nude mice with established
tumors were treated with intraperitoneal (i.p.) ATO 7.5 mg/kg
once daily, or oral itraconazole 75 mg/kg twice daily, or
Figure 4. ATO and Itraconazole Combine to
Inhibit Hh Pathway Activation and Tumor
Growth by SMOWT
(A and B) Effect of combination therapy on the
IC50 concentrations of itraconazole (A) or ATO
(B) in NIH 3T3 cells expressing endogenous
SMOWT stimulated with SHH-N in 83-GLI-lucif-
erase signaling assays. Data represent mean of
triplicates ± SD.
(C and D) Nude mice with SMOWT hindflank
MB allografts were treated with vehicle control
(40% cyclodextrin orally twice daily, n = 7 tumors;
black), GDC-0449 (100 mg/kg orally twice daily,
n = 7; red), ATO (7.5 mg/kg i.p. once daily, n = 7
tumors; green), itraconazole (75 mg/kg orally
twice daily, n = 7 tumors; blue), or both ATO and
itraconazole (n = 7 tumors; blue-green). Effect
of GDC-0449, ATO, itraconazole, or the combi-
nation of ATO and itraconazole on (C) tumor
growth and (D) Gli1 mRNA expression com-
pared to vehicle control. Data represent group
means ± SEM (*p < 0.01 versus vehicle; **p < 0.01
versus ATO alone; ***p < 0.01 versus itraconazole
alone).
See also Figure S3 and Tables S2 and S3.
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or itraconazole significantly inhibited tumor growth (Figure 4C),
and was associated with 78% (p < 0.005) and 96% (p < 0.001)
growth inhibition, respectively, as compared to vehicle-treated
tumors on day 9 of treatment. During the same vehicle-
controlled time period, the combination of ATO and itraconazole
not only inhibited tumor growth, but also reduced tumor
volumes by 72% from the start of treatment (p < 0.001
versus vehicle; p < 0.001 versus initial volumes). Combination
treatment compared to ATO or itraconazole alone significantly
improved antitumor efficacy, with 99% and 85% inhibition of
tumor growth relative to ATO or itraconazole alone through the
single-agent controlled portions of study, on days 13 and 17,
respectively (Figure 4C; p < 0.001 for both). ATO and itracona-
zole were well tolerated, both as single agents and in combina-
tion, as body weights were similarly maintained across cohorts
(Figure S3C).
Inhibition of MB tumor growth was associated with parallel
reductions in Hh pathway activity in treated tumors (Figure 4D).
Compared to vehicle-treated tumors, single-agent ATO or itra-
conazole treatment resulted in 39% and 55% inhibition of tumor
Gli1mRNA expression, respectively (p < 0.01 for both), whereas
combined ATO and itraconazole suppressed tumor Gli1 mRNA
transcript levels by 77% (p < 0.001 versus vehicle and ATO
alone; p < 0.01 versus itraconazole alone).
We also monitored the status of the PI3K pathway and GLI2
in the treated tumors (Figures S3D–S3F), because PI3K
pathway activation and GLI2 amplification and overexpression
have been reported as mechanisms of resistance to cyclop-
amine-competitive antagonists (Buonamici et al., 2010;
Dijkgraaf et al., 2011). Tumors with Hh pathway inhibition
(Figure 4D) displayed a low level of PI3K pathway activation
at baseline, evidenced by phosphorylation of AKT, S6K,
and 4E-BP1 (reviewed in Cully et al., 2006) that was largelyunchanged in response to the single-agent or combina-
tion treatments (Figure S3D). Tumors that eventually pro-
gressed during drug therapy (Figure 4C) did not show
increased levels of pAKT and pS6K (Figure S3E), nor did
they display increased Gli2 mRNA (Figure S3F). These results
suggest that the previously described mechanisms of resis-
tance to GDC-0449 and LDE225 are not the cause of eventual
tumor growth with itraconazole and ATO treatment, which
more likely is caused by incomplete, albeit substantial,
pathway suppression.
Additionally, in a subcutaneous allograft model of BCC
derived from Ptch+/;K14-CreER2/+;p53fl/fl mice (Tang et al.,
2011), the combination of itraconazole and ATO significantly in-
hibited tumor growth compared to control (p < 0.001 at day 30 of
treatment) (Figure 5). Mice treated with single agents displayed
reductions in mean tumor growth that did not reach statistical
significance compared to control.
Combination of Itraconazole and ATO Can Inhibit Hh
Pathway ActivityMediated byGDC-0449-Resistant SMO
In Vitro and In Vivo
Having established efficacy of the itraconazole/ATO combina-
tion for antagonism of SMOWT activity in vitro and in vivo, we
tested the combination against the GDC-0449-resistant SMO
mutant, SMOD477G (Yauch et al., 2009). We previously showed
that ATO can inhibit SMOD477G activity (Kim et al., 2010a). In
SHH-N-stimulated Smo/ MEFs transfected with SmoD477G,
addition of ATO to itraconazole inhibited Hh pathway activation
in a dose-dependent fashion (Figure 6A) and led to improved
inhibition by itraconazole at higher doses (Figure 6B), indicating
a greater potency for the combination. Similar to SMOWT
(Figures 4A and 4B), ATO and itraconazole inhibited SMOD477G
activity additively (Figure 6C; Figure S4A; Table S4), with no left-
ward IC50 shift (Figure S4A; Table S4).Cancer Cell 23, 23–34, January 14, 2013 ª2013 Elsevier Inc. 27
Figure 5. Combination of ATO and Itraconazole Inhibits Tumor
Growth of Hh-Dependent BCC
NOD/SCID mice with established K14-CreER/+;Ptch+/;p53fl/fl BCC allografts
were treated with vehicle control (40% cyclodextrin orally twice daily, n = 4
tumors; black), ATO (7.5mg/kg i.p. once daily, n = 6 tumors; green), itraco-
nazole (75 mg/kg orally twice daily, n = 10 tumors; blue), or both ATO
and itraconazole (n = 16 tumors; blue-green; p < 0.01 for the combina-
tion compared to either itraconazole or ATO alone). Data represent group
means ± SEM.
Cancer Cell
Targeting GDC-0449-Resistant Hh SignalingWe tested combination treatment in vivo in a GDC-0449-resis-
tant Ptch+/;p53/ murine MB allograft model expressing
endogenous SMOD477G (Yauch et al., 2009). In contrast to the
results observed in SMOWT tumors (Figure 4C), twice-daily treat-
ment with GDC-0449 did not significantly impact tumor growth
or Hh pathway status compared to control (Figures 6D and
6E). Of note, a similar albeit less dramatic differential was
associated with once-daily treatment with HhAntag treatment
in this model (Figures S4B–S4D). Unlike GDC-0449, ATO and
itraconazole inhibited SMOD477GMB growth with similar potency
to that of SMOWT tumors. In GDC-0449-resistant tumors, sin-
gle-agent ATO and itraconazole resulted in 78% and 92%
growth inhibition, respectively, versus control through the
9-day vehicle-controlled period (p < 0.001 for both). Combina-
tion treatment over the same period completely inhibited tumor
growth and caused 48% tumor regression from the start of study
(p < 0.001 versus vehicle; versus initial volumes). Furthermore,
the efficacy of the combination was superior to either agent
alone, and resulted in 97% relative tumor growth inhibition
over ATO alone (p < 0.001) and 85% improvement over itracona-
zole alone (p < 0.001) through the 12-day period controlled by the
respective single-agent arms (Figure 6D).
Treated tumors revealed that single-agent itraconazole and
ATO inhibited Hh pathway activity in GDC-0449-resistant
allografts (Figure 6E) with similar magnitudes of 43% and 45%
of control-treated tumors, respectively, as measured by Gli1
mRNA transcript (p < 0.01 for both). Combination treatment
resulted in further pathway suppression to 66% (p < 0.01). Gli1
mRNA expression was not significantly inhibited (p > 0.05) in
response to GDC-0449.
The hindflank allograft model of SMOD477G MB serves as
a valuable proxy for antitumor potential in the context of GDC-
0449 resistance. However, the ectopic nature of this model fails
to account for the challenges of treating an advanced intracranial
malignancy. To further evaluate the potential clinical relevance of
itraconazole and ATO in MB treatment, we assessed survival in
an orthotopic model of SMOD477G MB. Survival of mice bearing28 Cancer Cell 23, 23–34, January 14, 2013 ª2013 Elsevier Inc.engrafted intracranial tumors did not improve with GDC-0449,
because both treatment and control resulted in median survival
times of 14 days (Figure 6F, red and black lines, respectively;
p = 0.69). In contrast, survival of mice receiving single-agent
treatment with ATO or itraconazole (Figure 6F, green or blue
lines, respectively) improved significantly over control, with
median survival times of 18 days (p = 0.0041) and 22 days (p =
0.0001). The combination of these drugs (Figure 6F, blue-green
line) further improved survival over either single-agent alone (p
% 0.0001) and doubled the survival time over GDC-0449 and
vehicle arms, with a median survival of 29 days (p < 0.0001
compared to vehicle or GDC-0449 arms).
Combination of Itraconazole and ATO Remains Active
in All Known Drug-Resistant SMO Mutations and
in the Context of GLI2 Overexpression
In addition to SMOD473H (murine SMOD447G), alanine scan
mutagenesis identified potential alterations of SMOE518 that
confer resistance to GDC-0449 (Dijkgraaf et al., 2011). Five resis-
tance mutants to another SMO antagonist, NVP-LDE225, have
also been reported in Ptch+/;p53/ and Ptch+/;Hic1+/ MB
models (Buonamici et al., 2010).We transiently transfected these
drug-resistant Smo mutants into Smo/ MEFs and induced
pathway activation with SHH-N CM. Cells were treated with
GDC-0449 0.5 mM (40 3 IC50; Robarge et al., 2009), NVP-
LDE225 0.5 mM (80 3 IC50; Buonamici et al., 2010), itracona-
zole 1.5 mM, ATO 2.5 mM, and a combination of itraconazole
and ATO. We confirmed previously reported resistance of the
various SMO mutants (Figure 7), including partial sensitivity of
SmoG457S to NVP-LDE225 (Figure 7C) consistent with an IC50
of 400 nM (Buonamici et al., 2010). SmoG457S was, however,
resistant to 50 nM NVP-LDE225 (8 3 IC50 of SMOWT;
Figure 7C).
Itraconazole inhibited activity of all known SMO resistance
mutants at similar levels to SMOD477G (Figure 7), except for
murine SMOE522K, which corresponds to human SMOE518.
SMOE522K was resistant to GDC-0449 and, unlike SMOD477G,
was almost completely inhibited by itraconazole (Figure 7B). Itra-
conazole 1.5 mM inhibited the NVP-LDE225-resistant mutants
(Figures 7C–7G), with a range of40% (Figure 7C) to60% (Fig-
ure 7D). The addition of ATO 2.5 mM to itraconazole was able to
completely inhibit the activity of these mutants. As expected,
higher doses of ATO completely inhibited all of the resistant
mutants (Figure S5), because ATO acts downstream of SMO.
We previously showed that ATO inhibits the Hh pathway
through inhibition of ciliary transport and degradation of the
GLI proteins (Kim et al., 2010a). We tested itraconazole and
ATO, alone and in combination, on NIH 3T3 cells that ectopically
overexpressed GLI2 with and without the addition of SHH-N CM
(Figure 7H). GLI2 overexpression alone caused elevated
pathway activity, and the addition of SHH-N CM further induced
Hh pathway activation. As expected, itraconazole inhibited
pathway activity induced by SHH-N but not by GLI2 overexpres-
sion (Figure 7H), because itraconazole acts upstream of GLI2
(Kim et al., 2010b). ATO, however, was able to inhibit pathway
activity induced by SHH-N and GLI2. The combination of itraco-
nazole and ATO inhibited pathway activity induced by both
SHHN and GLI2 overexpression to a similar extent as was
observed with ATO alone.
Figure 6. ATO and Itraconazole Combine to Inhibit SMOD477G Activity and TumorGrowth, and Improve Survival in anOrthotopicMedulloblas-
toma Model
(A–C) Smo/ MEFs were transfected with either SmoWT or SmoD477G and stimulated with SHH-N. Data represent mean of triplicates ± SD. (A) Relative Hh
pathway activity as assessed by relative 8 3 -GLI-luciferase expression in the presence or absence of itraconazole, ATO, or the combination. Dashed line
represents the level of pathway inhibition of SMOWT by itraconazole 1.5 mM. (B) Effect of the addition of increasing doses of ATO to itraconazole in cells expressing
SMOD477G. (C) Effect of increasing doses of itraconazole on the IC50 of ATO in cells expressing SMO
D477G.
(D and E) Nude mice with established SMOD477G MB allografts were treated with vehicle control (40% cyclodextrin orally twice daily, n = 8 tumors; black), GDC-
0449 (100mg/kg orally twice daily, n = 8; red); ATO (7.5mg/kg i.p. once daily, n = 8 tumors; green), itraconazole (75 mg/kg orally twice daily, n = 8 tumors; blue), or
both ATO and oral itraconazole (n = 8 tumors; blue-green); (D) tumor growth over time and (E) relativeGli1mRNA expression. Data represent groupmeans ± SEM
(*p < 0.01 versus vehicle; **p < 0.01 versus ATO alone; ***p < 0.01 versus ITRA alone).
(F) Kaplan-Meier survival analysis of an orthotopicmodel of SMOD477GMB treatedwith vehicle control (n = 9), GDC-0449 (n = 9), itraconazole (n = 9), ATO (n = 9), or
both ATO and itraconazole (n = 9) using the same doses as in (D).
See also Figure S4 and Table S4.
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Figure 7. Combination of ATO and Itra-
conazole Inhibits All Other Known Drug-
Resistant SMO Mutants and GLI2 Overex-
pression
(A–G) SHH-N stimulated Smo/ MEFs were
transfected with (A) SmoWT or mutant Smo
constructs resistant to (B) GDC-0449 or (C–G)
NVP-LDE225. The effects of itraconazole, ATO,
and the combination of both agents on Hh
pathway activity was assessed by relative 83-GLI-
luciferase activity. Labels in (B–G) indicate the
mutant SMO that was expressed.
(H) Effect of itraconazole, ATO, or the combination
on relative 83-GLI-luciferase activity in NIH 3T3
cells transfected with Gli2 ± SHH-N stimulation.
Data represent mean of triplicates ± SD.
See also Figure S5.
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Itraconazole, Cyclopamine Mimics, and SMO
Prior to our studies of itraconazole, most or all SMOmodulators,
including GDC-0449 and NVP-LDE225, were found to com-
pete with BODIPY-cyclopamine for binding to SMO, pre-
sumably by binding at closely overlapping sites. Recent studies
(Dijkgraaf et al., 2011; Nachtergaele et al., 2012; Tao et al., 2011),
however, reveal additional complexity. Tao et al. (2011)
show that several recently identified Hh antagonists compete
for binding with distinct subsets of BODIPY-cyclopamine
competitive Smo modulators, suggesting that the BODIPY-
cyclopamine binding pocket and nearby regions within30 Cancer Cell 23, 23–34, January 14, 2013 ª2013 Elsevier Inc.SMO may accommodate two non-
overlapping modulators simultaneously.
Furthermore, oxysterol agonists that
do not compete with BODIPY-cyclop-
amine (Dwyer et al., 2007) have been
shown to bind SMO directly (Nachter-
gaele et al., 2012), presumably at a
distinct site.
Itraconazole appears to act entirely
outside the BODIPY-cyclopamine bind-
ing pocket, because it fails to compete
with BODIPY-cyclopamine or the SMO
agonist, SAG (Kim et al., 2010b). We
cannot rule out the possibility that itraco-
nazole acts on SMO indirectly via another
molecule, because we do not have
a direct binding assay. Nonetheless, the
ability of itraconazole to inhibit all of the
SMO variants resistant to GDC-0449
and NVP-LDE225 is consistent with its
action on SMO at a distinct site from
that of cyclopamine and its mimics.
Although compounds that overcome
SMOD477G activity and act within the
BODIPY-cyclopamine pocket of SMO
have been reported (Dijkgraaf et al.,
2011; Tao et al., 2011), their inhibitory
activity against other SMO mutationsand their toxicity and pharmacological properties in patients
remain unknown.
Interestingly, itraconazole only partially inhibits the activity of
SMOD477G (Figure 2B) and the other mutants, except for
SMOE522K (Figure 7). Small molecule partial antagonists for the
GPCR mGlu5 receptor have been described (Lamb et al.,
2011; Rodriguez et al., 2005, 2010) that act as noncompetitive
allosteric inhibitors of the orthosteric endogenous ligand, gluta-
mate (Wood et al., 2011). By analogy, perhaps itraconazole
acts as an allosteric inhibitor of a currently undefined endoge-
nous SMO-interacting factor. The mutant SMO proteins may
exist in conformations that allow itraconazole to exert its inhibi-
tory function in an incomplete fashion.
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Dependent Tumors
We have shown that itraconazole and ATO, alone and in combi-
nation, inhibit Hh pathway activity and growth of in vitro cultured
cells and in vivo tumors bearing wild-type and drug-resistant
SMO. The eventual, albeit significantly delayed, in vivo tumor
growth from itraconazole and ATO treatment is not due to
previously described resistance mechanisms of PI3K-mTOR
activation or Gli2 amplification (Figures S3D–S3F). Induction
of P-glycoprotein (PGP) and drug efflux, recently reported
(Lee et al., 2012) as a resistance mechanism to IPI-926, is
unlikely to be the case in our studies because itraconazole is
a potent inhibitor of PGP (Wang et al., 2002). The tumor growth
kinetics in our studies more likely reflect the incomplete albeit
substantial degree of Hh pathway inhibition by itraconazole
and ATO; this incomplete inhibition might be improved by
adjusting the relative or overall dosages of itraconazole and
ATO in the combination. Other mechanisms to account for the
eventual tumor regrowth, however, cannot be fully excluded at
this time.
Itraconazole also has been reported to inhibit mTOR activity
(Xu et al., 2010), and ATO has been reported to upregulate
PTEN (Redondo-Mun˜oz et al., 2010) and degrade AKT (Mann
et al., 2008). However, we did not observe significant changes
in PI3K pathway activity in our short-term (Figure S3D) or long-
term (Figure S3E) analyses. Several reasons may account for
the apparent discrepancy. First, the studies cited for the activity
of itraconazole and ATO against the PI3K pathway were all per-
formed in cell culture systems with robust activation of the PI3K
pathway, and may not accurately reflect the in vivo environment
examined here. Second, the marginal detection of PI3K pathway
activation in our in vivo tumor models suggest that this pathway
contributes little to tumor growth, and that further inhibition by
pharmacologic means may not be possible.
The therapeutic regimen of itraconazole and ATO combination
is active against all reported functional SMO resistance mutants
and has several advantages over single-agent SMO inhibition. In
addition to Hh pathway inhibition, itraconazole inhibits angiogen-
esis through vascular endothelial growth factor and fibroblast
growth factor (FGF) blockade (Aftab et al., 2011; Chong et al.,
2007; Nacev et al., 2011). Likewise, ATO induces apoptosis by
caspase activation, BCL2 inhibition, and reactive oxygen
species accumulation, NF-kB inhibition (Emadi and Gore,
2010), and the promotion of GLI protein degradation (Kim
et al., 2010a). The combination of itraconazole and ATO simulta-
neously targets two distinct and critical loci within the Hh
pathway: SMOandGLI proteins. Suchmultifocal targeting within
the Hh pathway itself and other pathways necessary for tumor
growth may prevent or delay the emergence of resistant tumor
clones. Moreover, the additive inhibitory effect of the itracona-
zole/ATO combination allows for the use of lower doses of
each drug to maintain or improve antitumor efficacy while
decreasing the likelihood of adverse toxicities. Finally, our data
suggest that ATO, alone or in combination with itraconazole,
may also inhibit tumor growth associated with GLI2-mediated
resistance (Figure 7H; Kim et al., 2010a).
With the recent FDA approval of GDC-0449 for advanced BCC
and with multiple other cyclopamine mimics in clinical trials, we
anticipate that examples of clinical resistance and other drug-resistant SMO mutants will become more prevalent. This repre-
sents a substantial threat to patients and emphasizes the need to
identify clinical candidates capable of maintaining on-target effi-
cacy in the face of such mutations. Itraconazole and ATO are
both FDA-approved drugs that are well tolerated, readily avail-
able, and with well-characterized pharmacokinetic and toxicity
profiles. We have shown that the combination of itraconazole
and ATO is effective against SMOWT, the recently reported
SMO mutants resistant to cyclopamine-mimics, and against
GLI2 overexpression. These factors strongly support the clinical
evaluation of itraconazole and ATO in the treatment of de novo
Hh-dependent tumors or those with acquired resistance to
cyclopamine mimics.
EXPERIMENTAL PROCEDURES
Detailed procedures can be found in Supplemental Experimental Procedures.
Reagents
Itraconazole (Sigma), vismodegib (GDC-0449; LC Laboratories), and NVP-
LDE225 (LC Laboratories) were dissolved in dimethyl sulfoxide for in vitro
experiments. ATO powder (Sigma) for in vitro experiments was formulated
as previously described (Zhu et al., 2002). Itraconazole oral solution (Spora-
nox, Ortho Biotech) and ATO (Trisenox; Cephalon) for in vivo experiments
were obtained from the pharmacies of The Johns Hopkins and Stanford
Cancer Centers. For in vivo studies, GDC-0449 100 mg/kg oral gavage (twice
daily), ATO 7.5mg/kg i.p. (once daily), and itraconazole 75 mg/kg orally (twice
daily) were used both as single agents and in combination.
Cell-Based Signaling Assays
Plasmid constructs for SmoWT or SmoD477G,Gli2 (Kim et al., 2010a),GFP, GLI-
dependent firefly luciferase reporter, and TK-Renilla luciferase reporter (Tai-
pale et al., 2000) have been described previously. Constructs for other Smo
resistance mutants were prepared using standard site mutagenesis tech-
niques to pCEFL-SmoWT and verified by DNA sequencing. Fugene 6 (Roche
Applied Science) or TransIT (Mirus Bio) reagents were used for transient
transfections.
NIH 3T3 cell line (ATCC) and Smo/ MEF cell line (Varjosalo et al., 2006)
were stimulated with SHH-N CM (Maity et al., 2005) or control HEK293 CM
for Hh pathway signaling assays.
Cells were incubated for 40 hr with drug treatments. Relative luciferase
(fold induction) units were obtained by normalization of luciferase signals
from SHHN CM stimulated with control CM stimulated cells. Luminescence
assays were performed on a Fluostar Optima (BMG Labtech) or Centro
(Berthold Technologies) using Dual Luciferase Assay Reporter System
(Promega).
In Vivo Studies
All mouse studies were approved by and conformed to the policies and regu-
lations of the respective Institutional Animal Care and Use Committees at the
Johns Hopkins University and the Children’s Hospital Oakland Research
Institute.
BCC Allograft Model
Endogenous BCC tumors from Ptch1+/; K14-CreER; p53fl/fl mice (Tang et al.,
2011) were subcutaneously established as flank xenografts in NOD/SCIDmice
(Jackson Laboratories). Oral itraconazole was given twice daily on weekdays
and once daily on weekends. ATO was given i.p. on a once-daily schedule.
Medulloblastoma Allograft Models
A parental murine MB model, expressing wild-type SMO, was derived from
spontaneous, intracranial MB from Ptch+/; p53/ mice and maintained as
subcutaneous hindflank allografts in athymic nude mice. GDC-0449-resistant
allografts expressing SMOD477G (SG274) were derived from parental allografts
as previously described (Yauch et al., 2009). Hindflank or orthotopic xenograft
models were generated from either parental or SG274 tissues.Cancer Cell 23, 23–34, January 14, 2013 ª2013 Elsevier Inc. 31
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MB tumorsphere cultures were derived from either parental or SG274 hind-
flank allografts using previously described methods (Shi et al., 2011). Tumor-
sphere proliferation was quantified by MTS assay following a 96 hr treatment
to the various drugs using exposure CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega).
Quantitative PCR of Gli1 and Gli2 Transcripts in Medulloblastoma
Systems
Established MB tumorspheres were treated for 24 hr with the various drugs.
Tissue from tumor-bearing mice were treated for 3 days and harvested 4 hr
after the last dose. Relative mRNA was quantified using TaqMan gene probes
for Actin,Gli1, andGli2 as previously described (Shi et al., 2011), and reported
as fold induction relative to control samples using the DDCt (2DDCt) method
with actin as an internal control.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2012.11.017.
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